Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant plus PF-07220060 in ER-positive/HER2-negative advanced or metastatic breast cancer
CTR20242782Phase 2Active
- Sponsor
- Pfizer
- Start
- Nov 2024
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vepdegestrant, atirmociclib in breast cancer, sponsored by Pfizer. Started Nov 2024; status: active.
02
Drugs
vepdegestrantatirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20242782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242782.